FDA approves 200 mg prefilled Dupixent pen for at-home use

A 200 mg single-dose prefilled pen for Dupixent has been approved by the FDA for at-home use to treat certain patients with atopic dermatitis and asthma, according to a company announcement.

The Dupixent pen (dupilumab, Regeneron) is for patients aged 12 years and older and is expected to be available in the United States in August 2021.

A 300 mg dose of the prefilled pen was previously approved by the FDA in June 2020.